For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Potential cost to patient safety as New Zealand debates access to medicinal cannabis
+Print Archive
Practice
Potential cost to patient safety as New Zealand debates access to medicinal cannabis
Wednesday 28 August 2019, 02:30 AM

The New Zealand Government is introducing a scheme for regulating medicinal cannabis
CLINICAL COMMENT
Michelle Glass and John Ashton from the University of Otago discuss whether untested cannabis-based products should enter the New Zealand healthcare system, as proposed by the Government’s recent consultation document
Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any pr
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.